Data from ongoing Phase 1 study of AX-0810 in healthy volunteers demonstrated dose-dependent target engagement on all key ...
Evommune, Inc. (NYSE: EVMN) (the "Company" or "Evommune"), a clinical-stage biotechnology company developing innovative ...
Sionna Therapeutics targets cystic fibrosis with novel CFTR/NBD1 stabilization; key 2026 readouts and cash runway to 2028.
Findings provide mechanistic support for previously reported clinical outcomes of clinical reversal of platinum resistance/refractoriness from ...
Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced positive topline full study results from the Phase 3 VISIONARY trial. VOYXACT ® ...
A new approach for identifying signs of hidden awareness in people who cannot speak or move after severe brain injury has ...
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today provides shareholders a ...
The wAIHA market landscape is undergoing a significant evolution after years of dependence on broad immunosuppressive ...
You'll come for the hands-on tweaking and wealth of features, and quickly forgive some of the workflow issues when you hear ...
Multi-omics analyses identifies linoleic acid as a critical fatty acid which is modulated by ART26.12SOLANA BEACH, Calif., ...
NeuroSense Therapeutics Ltd. ("NeuroSense"), a late-stage clinical biotechnology company focused on developing ...
AVXL rated Hold: strong $131.7M cash runway, but blarcamesine’s upside hinges on clearer efficacy and FDA approval.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results